Immunotoxicity Skimune - Testing Platform

Preclinical safety and efficacy testing of drugs as “first in man studies”, sensitisation testing of chemicals and cosmetics, safety and efficacy testing of cellular therapies. Human in vitro tests as alternative to animal models.

Most popular related searches

small molecule drug

small-molecule drug

Rapid identification of adverse immune responses not identified in animal models

Human model, more sensitive and more predictive of clinical outcome than animal models

Uses human cells and tissue; incorporates multiple key events of the adverse outcome pathway (AOP)

Can test a range of different compounds e.g. small molecule drugs, monoclonal antibodies, cellular therapies, raw materials, end products and more

Incorporates. T-cell proliferation responses, cytokine responses, skin explant histopathology

Highly predictive e.g. tested >200 compounds and shows 80-90% accuracy

Highly customised assay

Predicts adverse immune responses to compounds demonstrating if the compound has the potential to activate the human immune system , with DC/T cell activation, cytokine release and histopathology associated with allergy, hypersensitivity or sensitisation responses.

Immunotoxicity Skimune - Testing Platform

Benefits

Key Capabilities